Back to
Miller Value Partners, LLC
HALO
6 quarters
Position history for
Miller Value Partners, LLC's holdings in Halozyme Therapeutics, Inc.
No. Miller Value Partners exited its HALO (Halozyme Therapeutics) position in Q1 2020. Its Q4 2019 13F listed 20,000 shares worth $355,000. Miller Value Partners already held HALO in its Q4 2018 13F, the earliest on record, and held it in 5 quarterly 13F filings.
Final Value
$0
Final Shares
0
Total Value Change
-$293,000
Total Shares Change
-20,000
Quarter-by-Quarter History
Other major holders of HALO: BlackRock, Inc., BlackRock Finance, Inc.